REG - Wells Fargo & Co - Publication of a Supplementary Prospectus

RNS Number : 1342P Wells Fargo & Company 15 January 2026 Publication of Supplementary ProspectusThe following prospectus has been approved by the Financial Conduct Authority and is available for viewing:Supplementary prospectus dated 15 January 2026 (the "Supplementary Prospectus") supplementing the base prospectus dated 4 April 2025 relating to the Wells Fargo & Company U.S.$50,000,000,000 euro medium term note programme, as supplemented by the supplementary prospectuses dated 30 April 2025, 20 June 2025, 6 August 2025 and 3 November 2025 (together the "Base Prospectus").To view the full document, please click on or paste the following URL into the address bar of your browser:http://www.rns-pdf.londonstockexchange.com/rns/1342P_1-2026-1-15.pdfhttp://www.rns-pdf.londonstockexchange.com/rns/1342P_1-2026-1-15.pdfA copy of the Supplementary Prospectus will be submitted to the National Storage Mechanism and will shortly be available for inspection at:https://data.fca.org.uk/#/nsm/nationalstoragemechanismFor further information, please contact:Sandra GalvisAssistant General Counsel, Executive Director and Assistant SecretaryWells Fargo & Companysandra.j.galvis@wellsfargo.comDISCLAIMER - INTENDED ADDRESSEESPlease note that the information contained in the Supplementary Prospectus or Base Prospectus (collectively, the "Prospectus") may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus is not addressed. Prior to relying on the information contained in the Prospectus you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.Your right to access this service is conditional upon complying with the above requirement. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END PSPFZGMMNKFGVZM